BioBridgeX
Log inCompare quotes
Modality

Antibody-Drug Conjugate (ADC) CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing an antibody-drug conjugate means handing off three linked problems: the antibody, the cytotoxic payload and linker chemistry, and the bioconjugation that joins them under GMP. It needs CROs and CDMOs with HPAPI containment, conjugation and analytical depth, and DAR control. On BioBridgeX, buyers source and compare qualified ADC suppliers in one place, free for buyers.

Antibody-Drug Conjugate (ADC) CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Antibody-Drug Conjugate (ADC) CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture an Antibody-Drug Conjugate (ADC) drug?

An ADC is three molecules pretending to be one. You have a monoclonal antibody that finds the tumor, a cytotoxic payload potent enough that a few molecules per cell can kill it, and a linker that holds the two together in circulation and then releases the payload where it should. Each part is a separate discipline, and the hard part of ADC work is that they have to behave as a single product through manufacturing, release testing, and a regulatory filing. A generalist biologics shop can make the antibody. A small-molecule house can make the payload. Far fewer can do the conjugation step in between and control it well enough to ship clinical material.

On the discovery and preclinical side the questions are about payload class (auristatin, maytansinoid, topoisomerase inhibitor, the newer immune-stimulating payloads), linker chemistry (cleavable versus non-cleavable, and how stable it is in plasma), and the conjugation method itself. Lysine and interchain-cysteine conjugation are the workhorses and give you a heterogeneous mixture; site-specific approaches (engineered cysteines, enzymatic tags, click chemistry) give a tighter, more defined product but add development work. The number that ties all of this together is DAR, the drug-to-antibody ratio, plus its distribution. DAR drives potency, pharmacokinetics, and aggregation, so analytical control of DAR is not a nice-to-have, it is the product specification.

The CMC and manufacturing side is where specialist ADC CDMOs separate from generalists, and the reason is containment. ADC payloads are high-potency APIs (HPAPI), often with occupational exposure limits in the nanogram range, so the conjugation suite needs isolators, closed processing, and a containment and industrial-hygiene program that an ordinary biologics or small-molecule plant does not have. On top of that you need the payload-linker synthesis, the bioconjugation step, purification (TFF, chromatography) to strip unconjugated payload, and a sterile fill-finish that can handle a cytotoxic drug product. Just as telling is the analytical package: DAR by HIC and mass spec, free-drug and residual-solvent assays, aggregate and charge-variant profiling, and a potency assay that reflects the conjugate, not just the naked antibody. A supplier who can run the chemistry but cannot characterize the molecule to a regulator's satisfaction will stall you at the IND.

How do you choose a CRO or CDMO for Antibody-Drug Conjugate (ADC)?

The first filter is whether the supplier actually does conjugation, not just one of the three pieces around it. Plenty of capable antibody manufacturers and plenty of capable HPAPI chemistry houses will tell you they support ADCs because they own one part of the chain. What you want, especially early, is either a single CDMO that runs payload-linker, conjugation, purification, and fill-finish under one roof, or a small set of partners with a clear interface and a track record of working together. Each handoff of cytotoxic material between sites is a containment, shipping, and analytical-comparability problem, so fewer seams is usually fewer delays.

Use the checklist below when you put two or three suppliers against the same written scope and the same target DAR and timeline.

  • Relevant platform and track record: confirm they have run your conjugation chemistry (lysine, interchain-cysteine, or site-specific) and a payload of your class, ideally on a molecule that reached IND or beyond, not just a feasibility batch.
  • HPAPI containment and GxP: isolator-based or closed conjugation suites, a defined occupational exposure band for your payload, and the right quality system for the phase you are at (GMP for clinical supply, documented GLP feeding the tox package).
  • Analytical capability for this modality: in-house DAR by HIC and intact-mass, free-drug and residual-payload methods, aggregate and charge-variant analysis, and a conjugate potency assay. Ask to see method development data, not just a capability list.
  • Capacity and scale: realistic queue for an isolator suite (containment capacity is the bottleneck in this industry, not stainless steel), and a credible path from grams of clinical material to a commercial scale you can name.
  • Regulatory experience: prior INDs or BLAs with an ADC component, comfort with FDA and EMA expectations on DAR specification and comparability, and experience writing the conjugation and characterization sections of a regulatory filing.
  • IP and confidentiality: a CDA before you disclose the linker or payload, clear ownership of process and analytical know-how generated on your program, and clarity on whether any of their conjugation or linker technology is licensed or carries downstream royalties.

Frequently asked questions

What is the difference between a CRO and a CDMO for an ADC program?
A CRO runs studies for you: discovery screening, in vitro and in vivo pharmacology, bioanalysis, and the GLP toxicology that supports your IND. A CDMO makes material: the payload-linker, the antibody, the conjugation step, and GMP drug substance and drug product. For an ADC the line blurs because the conjugation step sits between development and manufacturing, and several specialist shops do both the process development and the GMP supply. In practice you often use a CRO for the biology and tox and a CDMO (or a couple of them) for the chemistry, conjugation, and fill-finish.
Why do ADCs need specialist HPAPI containment?
ADC payloads are extremely potent cytotoxics, frequently with occupational exposure limits in the single-digit nanogram-per-cubic-meter range, far below what a normal biologics or small-molecule facility is built to handle. Conjugation has to happen in isolators or closed systems with a real containment and industrial-hygiene program protecting operators and preventing cross-contamination. This is the single biggest reason ADC work costs more and has fewer qualified suppliers: most plants physically cannot process the payload safely, and building or qualifying that capacity is slow.
What is DAR and why does it matter so much?
DAR is the drug-to-antibody ratio, the average number of payload molecules attached to each antibody, and it comes with a distribution around that average. DAR drives potency, clearance and pharmacokinetics, aggregation, and tolerability, so it is a core product attribute. Conjugation chemistry largely sets it: lysine and interchain-cysteine methods give a heterogeneous spread, while site-specific methods give a tighter, more defined DAR. Because so much rides on it, your CDMO needs validated analytics (HIC, intact-mass and peptide-mapping by mass spec) to measure and control DAR batch to batch, and it becomes a release specification in your filing.
Should I use one CDMO for the whole ADC or split the work across suppliers?
Both models ship approved drugs, so it is a tradeoff rather than a rule. A single end-to-end CDMO that handles payload-linker, antibody, conjugation, purification, and fill-finish removes handoffs, which matters because every transfer of cytotoxic material is a containment, shipping, and analytical-comparability exercise. A multi-supplier model lets you pick the best group for each step (a strong antibody manufacturer plus a specialist conjugation house) and can be cheaper or faster if those suppliers already interface cleanly. Early in development most teams favor fewer seams; at commercial scale, capacity and cost can justify splitting.
How long does ADC process development and clinical manufacturing take?
Treat any single number with caution, because ADC timelines depend on whether you are using a known conjugation platform or developing a new one. A program on an established chemistry with material in hand can move from process development to a GMP clinical batch in roughly a year, and longer when you are optimizing a site-specific method, qualifying new analytical methods for DAR and free drug, or waiting on isolator-suite capacity. The conjugation step itself is fast; the development, analytical method qualification, and containment scheduling around it are what set the calendar.
Who owns the process and analytical know-how developed during an ADC program?
Settle this in writing before work starts. In a well-structured arrangement you own the process and analytical methods developed specifically for your molecule, plus the data and regulatory documentation. The complication with ADCs is that the supplier's conjugation chemistry or linker technology may be their proprietary or licensed platform, which can carry usage rights, field-of-use limits, or downstream royalties. Get the boundary between your program-specific IP and their background platform IP defined explicitly, and confirm any third-party licenses behind their linker or conjugation method before you commit.

Source Antibody-Drug Conjugate (ADC) work with one contract

Compare transparent quotes from qualified Antibody-Drug Conjugate (ADC) CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes